Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A model for the Dutch pharmaceutical market.

E Canton1, E Westerhout

  • 1CPB-Netherlands Bureau for Economic Policy Analysis, The Hague, Netherlands. canton@cpb.nl

Health Economics
|September 2, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent <i>Candida</i> spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability.

Antimicrobial agents and chemotherapy·2021
Same author

Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in <i>Candida</i> and <i>Aspergillus</i> Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods.

Antimicrobial agents and chemotherapy·2018
Same author

Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method.

Antimicrobial agents and chemotherapy·2016
Same author

In vitro activity of anidulafungin in combination with amphotericin B or voriconazole against biofilms of five Candida species.

The Journal of antimicrobial chemotherapy·2016
Same author

In Vitro Studies of Tigemonam: a Comparison of the Minimum Inhibitory and Minimum Bactericidal Concentrations (MIC vs MBC).

Journal of chemotherapy (Florence, Italy)·2016
Same author

Erratum to: Species distribution and in vitro antifungal susceptibility profiles of yeast isolates from invasive infections during a Portuguese multicenter survey.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2015
Same journal

Health on the Move: The Impact of Poverty Alleviation Relocation on Healthcare Utilization in China.

Health economics·2026
Same journal

The Effects of Compulsory Licensing: A Case Study of HIV Drugs.

Health economics·2026
Same journal

Beyond Tobacco Prevention: The Effects of Tobacco 21 Laws on Young Adults' Body Weight.

Health economics·2026
Same journal

Assessing the Estimands and Estimates of Hospitalization Rates in Health Economics and Clinical Medicine.

Health economics·2026
Same journal

The Impact of Unemployment Insurance Benefit Cuts on Mental Health: Evidence From Early Pandemic Program Expirations.

Health economics·2026
Same journal

Do Patients Value the Service Provided by Physicians Who Overbill? A Willingness-to-Pay Study Using French Survey Data.

Health economics·2026
See all related articles

This study models the Dutch pharmaceutical market to analyze policy impacts on healthcare costs. General-equilibrium analysis reveals unexpected effects of drug distribution incentives and market competition.

Area of Science:

  • Health Economics
  • Pharmaceutical Market Analysis
  • General Equilibrium Theory

Background:

  • The Dutch pharmaceutical market involves complex interactions between patients, pharmacists, drug producers, and parallel-importers.
  • Partial-equilibrium approaches may not fully capture the system-wide effects of policy changes in this market.

Purpose of the Study:

  • To develop a general-equilibrium model of the Dutch pharmaceutical market.
  • To evaluate the impact of various policy interventions on pharmaceutical care expenditures.

Main Methods:

  • Microeconomic principles were used to derive the behavior of market actors.
  • A calibrated general-equilibrium model was employed for policy simulations.
  • Policy experiments included cost-conscious distribution incentives, increased copayments, reduced trade barriers for parallel-importers, and generic drug market entry.

Related Experiment Videos

Main Results:

  • General-equilibrium effects on pharmaceutical care costs can differ significantly from partial-equilibrium predictions.
  • The model quantifies the impact of specific policies on overall healthcare spending.
  • Simulations provide insights into the economic consequences of market structure and regulatory changes.

Conclusions:

  • A general-equilibrium framework is essential for accurately assessing pharmaceutical market policies.
  • Policy interventions can have complex and sometimes counterintuitive effects on healthcare costs.
  • The model provides a valuable tool for policymakers in the Netherlands for pharmaceutical market regulation.